Patients with known hypersensitivity to any component of the chemotherapy regimen will not be eligible
Known prior severe hypersensitivity to the investigational products or any component in their formulations,
Known hypersensitivity to any component of the atezolizumab or cobimetinib formulations
Known hypersensitivity to any study drug component
Known hypersensitivity to any component of required drugs in the study
Participation in the DES component of the study.
The tumor must not have an infratentorial component;
Known allergy or hypersensitivity to phosphatidylinositol  kinase (PIK) inhibitors or any component of the formulations used in this study.
Subjects with known allergy or hypersensitivity to any component of the investigational product will be excluded
Known hypersensitivity to any component of study drug including potential subjects with a history of major immunologic reaction to any IgG-containing agent
An allergy to a component of Levulan
have a known or suspected allergy to the study drug or any study drug component;
Known prior hypersensitivity to the investigational product or any component formulations, including known severe hypersensitivity reactions to monoclonal antibodies
Known hypersensitivity to any component of the investigational products
Nonsecretory multiple myeloma based upon standard M-component criteria (i.e., measurable serum/urine M-component) unless the baseline serum free light chain level is elevated; patients with plasmacytomas with biopsy proven known mutations may be included as long as they have evaluable disease by imaging
Known allergy or hypersensitivity to any component of the investigational drug product.
Known hypersensitivity to any component of the nivolumab or ipilimumab product
Known hypersensitivity to immunoglobulins or any other component of the study drug
Known hypersensitivity to any component of the investigational product
Known hypersensitivity to any component of ado-trastuzumab emtansine
Known hypersensitivity to any study drug component.
Known hypersensitivity to any component of the product (lenvatinib or ingredients).
Serum M component (? . g/dL), or
History of hypersensitivity or allergic reaction to varenicline, NRT, or any component of these formulations
Known hypersensitivity to any component of Avastin
For tumors that are invasive, if in the presence of extensive intraductal component (EIC), the entire pathologic tumor size (including both the intraductal and invasive component) must be . cm or less.
Patient with documented hypersensitivity to any of the component medications
Known hypersensitivity to any component of axitinib or prior use of axitinib
Known hypersensitivity to any component of topotecan or doxorubicin or other required drugs in the study
Known hypersensitivity to any component of the study medication(s).
Subject has known immediate or delayed hypersensitivity, intolerance or contraindication to any component of study treatment.
Known prior severe hypersensitivity to investigational products or any component in their formulations
Participant has hypersensitivity to any component of TMZ or dacarbazine.
Known hypersensitivity to any temozolomide component or to dacarbazine (DTIC).
Patients with a known hypersensitivity to -aminolevulinic acid or any component of the study material
Known prior or suspected hypersensitivity to study drugs or any component in their formulations
History of allergy or hypersensitivity to any component of the treatment
Systemic hypersensitivity to Montanide ISA  VG or any vaccine component
Systemic hypersensitivity to Montanide ISA  VG or any vaccine component
Patients must not have any known allergy or reaction to any component of the nivolumab and ipilimumab formulations
Known hypersensitivity to any study drug component
Known anaphylaxis or IgE-mediated hypersensitivity to murine proteins or to any component of rituximab
Known hypersensitivity to any component of lenvatinib or midazolam.
Known hypersensitivity to a component of protocol therapy
Subjects with known allergy or hypersensitivity to any component of the investigational product will be excluded
A known allergy to any component of LY.
Known anaphylaxis or immunoglobulin E (IgE)-mediated hypersensitivity to murine proteins or to any component of rituximab
Tumor must have a supratentorial component
Extensive intraductal component
Known anaphylaxis or IgE-mediated hypersensitivity to murine proteins or to any component of rituximab.
Patients must not have known hypersensitivity reactions, such as urticaria, angioedema, bronchoconstriction, anaphylaxis, Steven-Johnson syndrome, and toxic epidermal necrolysis to interferon alpha or any other products component
Has a known hypersensitivity, intolerability or contraindication to any component of study treatment, including premedication
Participants who have known hypersensitivity to any component of loperamide or budesonide
History of allergy or hypersensitivity to any component of the study drugs
Cystic component >= % the total volume of the tumor
Known or suspected allergy or hypersensitivity to yeast or any other component of CRS- (e.g., glycerol), Platinol or platinum-containing compounds, or pemetrexed
Subjects with less than % intraductal component
Known hypersensitivity to any component of the trial agents
Known hypersensitivity to somatostatin analogues or any component of the pasireotide or octreotide long-acting release [LAR] formulations
History of known hypersensitivity to S. cerevisiae, bevacizumab or any component of FOLFOX or FOLFIRI; hypersensitivity skin test is required at screening to rule out allergy to S. cerevisiae
Known hypersensitivity to any component of recombinant protein production by CHO cells
Known allergy or hypersensitivity to any component of the study treatment(s)
Has a known hypersensitivity to cetuximab, murine proteins, or any component of cetuximab;
Known hypersensitivity to any component of study treatments that resulted in drug discontinuation
Hypersensitivity to PEG or other component of AEB (Co-ArgI-PEG)
Known hypersensitivity to any component of study treatments
Known hypersensitivity to any component of study treatments
Known anaphylaxis or IgE-mediated hypersensitivity to murine proteins or to any component of rituximab (Rituxan)
Known hypersensitivity to any component of study treatments that resulted in drug discontinuation
Known hypersensitivity to any component of study treatments
Previous known sensitivity to any Fibrin Sealant Grifols component or any Surgicel component.
Known or suspected hypersensitivity to any component of GVAX Pancreas vaccine or CRS-, or known allergy to both penicillin and sulfa
Subjects who are known or suspected to be hypersensitive to any component of the study medications.
Allergic to diphtheria toxin a component of the study drug A-dmDT-bisFv(UCHT).
Known hypersensitivity to any component of RDHAP
Known hypersensitivity to somatostatin analogs or any component of the pasireotide long acting release (LAR) or suspension concentrate (s.c.) formulations
Known hypersensitivity to any component of the atezolizumab product
Known hypersensitivity reaction to any component of ferric carboxymaltose
Known hypersensitivity to any component of testosterone
Hypersensitivity/allergy or contraindication to any component of the stent, delivery system, or medication required to complete the procedure,which in the investigator's opinion cannot be adequately premedicated
Educational component: men over the age of 
Screening component: men over age 
Documented hypersensitivity to any component of ranolazine (Ranexa) pills
Any known allergy or hypersensitivity to vaginal lubricants or any component of study product
History of hypersensitivity or allergic reaction to varenicline, NRT, or any component of these formulations
Known hypersensitivity to any component of the nivolumab or ipilimumab product
History of any reaction or hypersensitivity likely to be exacerbated by any component of the vaccine.
History of any reaction or hypersensitivity likely to be exacerbated by any component of the vaccine
History of allergy or hypersensitivity to any component of the treatment
Patients with known hypersensitivity or allergy to any component of Sonazoid.
Patients with known hypersensitivity or allergy to any component of Definity
Patients with known hypersensitivity to any component of Definity micro bubble contrast
Patients with history of hypersensitivity reaction to any component of Zr-DFO-MSTPA, including DFO
Allergy to any component of sipuleucel-T
